Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine

Psychosomatics

Volumn 47, Issue 4, 2006, Pages 348-352

  Denninger, John W ^a   Papakostas, George I ^a   Mahal, Yasmin ^a   Merens, Wendelien ^a   Alpert, Jonathan E ^a   Nierenberg, Andrew A ^a   Yeung, Albert ^a   Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; SCORING SYSTEM; STRUCTURED QUESTIONNAIRE; TREATMENT RESPONSE; ADOLESCENT; AMBULATORY CARE; MIDDLE AGED; QUESTIONNAIRE; SOMATOFORM DISORDER;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; SEROTONIN UPTAKE INHIBITORS; SOMATOFORM DISORDERS;

EID: 33747105945     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.47.4.348     Document Type: Article

References (36)

1. Fava M: Somatic symptoms, depression, and antidepressant treatment. J Clin Psychiatry 2002; 63:305-307
2. Simon GE, VonKorff M, Piccinelli M, et al: An international study of the relation between somatic symptoms and depression. N Engl J Med 1999; 341:1329-1335
3. Corruble E, Guelfi JD: Pain complaints in depressed inpatients. Psychopathology 2000; 33:307-309
4. Kroenke K, Price RK: Symptoms in the community: prevalence, classification, and psychiatric comorbidity. Arch Intern Med 1993; 153:2474-2480
5. Gerber PD, Barrett JE, Barrett JA, et al: The relationship of pre-senting physical complaints to depressive symptoms in primary-care patients. J Gen Intern Med 1992; 7:170-173
6. Terre L, Poston WS, Foreyt J, et al: Do somatic complaints predict subsequent symptoms of depression? Psychother Psychosom 2003; 72:261-267
7. Simon GE, Katon W, Rutter C, et al: Impact of improved depression treatment in primary care on daily functioning and disability. Psychol Med 1998; 28:693-701
8. Brody DS, Hahn SR, Spitzer RL, et al: Identifying patients with depression in the primary-care setting: a more efficient method. Arch Intern Med 1998; 158:2469-2475
9. Kroenke K: Patients presenting with somatic complaints: epidemiology, psychiatric comorbidity, and management. International Journal of Methods in Psychiatric Research 2003; 12:34-43
10. Kellner R: A symptom questionnaire. J Clin Psychiatry 1987; 48:268-274
11. Fava M, Dunner DL, Greist JH, et al: Efficacy and safety of mir-tazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry 2001; 62:413-420
12. Detke MJ, Lu Y, Goldstein DJ, et al: Duloxetine, 60 mg once daily, for major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2002; 63:308-315
13. Detke MJ, Lu Y, Goldstein DJ, et al: Duloxetine 60 mg once-daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002; 36:383-390
14. Papakostas GI, Petersen T, Denninger J, et al: Somatic symptoms in treatment-resistant depression. Psychiatry Res 2003; 118:39-45
15. Petersen T, Dording C, Neault NB, et al: A survey of prescribing practices in the treatment of depression. Prog Neuropsychophar-macol Biol Psychiatry 2002; 26:177-187
16. Small GW, Hamilton SH, Bystritsky A, et al: Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression: Fluoxetine Collaborative Study Group. Int Psychogeriatr 1995; 7(suppl):41-53
17. Spitzer RL, Williams JBW, Gibbon M, et al: Structured Clinical Interview for DSM-III-R, Patient Edition, (SCID-P). Washington, DC, American Psychiatric Press, 1990
18. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
19. Fava M, Alpert JE, Nierenberg AA, et al: A validation study of a computerized management system for the diagnosis and treatment of depression, in Proceeding of the 153rd Annual Meeting of the American Psychiatric Association. Washington, DC, American Psychiatric Association, 2000
20. Tedlow J, Fava M, Uebelacker L, et al: Outcome definitions and predictors in depression. Psychother Psychosom 1998; 67:266-270
21. Nierenberg AA, Keefe BR, Leslie VC, et al: Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999; 60:221-225
22. Fava M: The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. J Clin Psychiatry 2003; 64(suppl 13):26-29
23. Fava M, Mallinckrodt CH, Detke MJ, et al: The effect of dulox-etine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry 2004; 65:521-530
24. Sindrup SH, Jensen TS: Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999; 83:389-400
25. O'Malley PG, Jackson JL, Santoro J, et al: Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract 1999; 48:980-990
26. White PD, Cleary KJ: An open study of the efficacy and adverse effects of moclobemide in patients with the chronic fatigue syndrome. Int Clin Psychopharmacol 1997; 12:47-52
27. Natelson BH, Cheu J, Hill N, et al: Single-blind, placebo phase-in trial of two escalating doses of selegiline in the chronic fatigue syndrome. Neuropsychobiology 1998; 37:150-154
28. Natelson BH, Cheu J, Pareja J, et al: Randomized, double blind, controlled placebo phase-in trial of low-dose phenelzine in the chronic fatigue syndrome. Psychopharmacology (Berl) 1996; 124:226-230
29. Hickie IB, Wilson AJ, Wright JM, et al: A randomized, double-blind, placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome. J Clin Psychiatry 2000; 61:643-648
30. Hannonen P, Malminiemi K, Yli-Kerttula U, et al: A randomized, double-blind, placebo-controlled study of moclobemide and ami-triptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol 1998; 37:1279-1286
31. Goldenberg D, Mayskiy M, Mossey C, et al: A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996; 39:1852-189
32. Cantini F, Bellandi F, Niccoli L, et al: [Fluoxetin combined with cyclobenzaprine in the treatment of fibromyalgia]. Minerva Med 1994; 85:97-100
33. Norregaard J, Volkmann H, Danneskiold-Samsoe B: A randomized, controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995; 61:445-449
34. Vercoulen JH, Swanink CM, Zitman FG, et al: Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet 1996; 347:858-861
35. Wolfe F, Cathey MA, Hawley DJ: A double-blind, placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994; 23:255-259
36. Ansari A: The efficacy of newer antidepressants in the treatment of chronic pain: a review of current literature. Harv Rev Psychiatry 2000; 7:257-277